Log in to search using one of your social media accounts:

 

What is the Compaction Triangle?
Gamlen presents three key parameters to visualising compacted material properties. (Source: Drug Development Technology)
Source: Drug Development Technology - May 12, 2017 Category: Pharmaceuticals Source Type: news

Sierra to amend two ongoing Phase I trials of SRA737 in UK
Canadian-based drug development firm Sierra Oncology has received clearance from UK regulatory authorities to amend two of its ongoing Phase I clinical trials of SRA737 within the country. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Corium ’s Corplex Donepezil demonstrates positive outcome in pilot BE trial
US-based Corium International has reported positive preliminary results from a pilot bioequivalence (BE) clinical trial of Corplex Donepezil in healthy subjects. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Aimmune ’s Phase III trial commences enrolment to study AR101 for peanut allergy
Aimmune Therapeutics has commenced patient enrolment in a Phase III RAMSES (ARC007) clinical trial of AR101 to treat peanut allergy. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

M & As this week: INC Research Holdings, WIRB-Copernicus Group (WCB)
US-based contract research organisation INC Research Holdings and contract commercial organisation inVentiv Health are set to merge to form the world ’s second biggest biopharmaceutical outsourcing provider. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: OptiNose, Dermira, Aadi Bioscience
OptiNose has completed a series D venture financing round to raise funds required for the commercialisation and launch of its lead product candidate, OPN-375, in the US. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Top 10 Factors When Choosing a DLS Instrument
The physical components and features of a dynamic light scattering (DLS) instrument, along with the instrument's technical specifications, are important when purchasing a new system. (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

Boehringer begins enrolment in Phase II trial of BI 655064 to treat lupus nephritis
Pharmaceutical company Boehringer Ingelheim has begun patient enrolment in the Phase II clinical trial of BI 655064 for the treatment of lupus nephritis (LN). (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news

DrugDev and Informa partner to enable easy site identification for clinical trials
DrugDev and Informa ’s Pharma Intelligence vertical, Citeline, have integrated their respective platforms to allow easy and efficient identification of ideal sites for conducting clinical trials. (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news

OncoSec and Merck to begin Phase II combination trial to treat metastatic melanoma
US-based biotechnology company OncoSec has entered a clinical trial collaboration and supply agreement with Merck to begin the Phase II PISCES clinical trial of ImmunoPulse IL-12 and keytruda combination for the treatment of patients with metastatic … (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2017 Category: Pharmaceuticals Source Type: news

AbbVie ’s ABT-494 demonstrates positive outcome in Phase II trial for Crohn's disease
AbbVie has reported positive results from the Phase II CELEST clinical trial of upadacitinib (ABT-494) for the treatment of patients with Crohn's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 9, 2017 Category: Pharmaceuticals Source Type: news

Abeona to initiate Phase I/II trial of ABO-102 in Australia to treat MPS IIIA
US-based biopharmaceutical company Abeona Therapeutics has secured regulatory approval from the Australian Health Therapeutic Goods Administration to commence a Phase I/II clinical trial of its ABO-102 for the treatment of Sanfilippo syndrome type A … (Source: Drug Development Technology)
Source: Drug Development Technology - May 9, 2017 Category: Pharmaceuticals Source Type: news

resTORbio begins Phase IIb mTORC1 inhibitors trial
US-based clinical-stage biopharmaceutical company PureTech Health subsidiary resTORbio has initiated a Phase IIb study of its mechanistic target of rapamycin complex 1 (mTORC1) programme. (Source: Drug Development Technology)
Source: Drug Development Technology - May 9, 2017 Category: Pharmaceuticals Source Type: news

Embera reports positive topline data from Phase Ib cocaine interaction study of EMB-001
US-based clinical-stage pharmaceutical firm Embera NeuroTherapeutics has reported positive topline data from the Phase Ib cocaine interaction study of a patented combination product EMB-001. (Source: Drug Development Technology)
Source: Drug Development Technology - May 8, 2017 Category: Pharmaceuticals Source Type: news

Genfit's Phase IIa trial of elafibranor begins patient enrolment
French biopharmaceutical company Genfit has begun patient enrolment for the Phase IIa clinical trial of elafibranor to treat primary biliary cholangitis (PBC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 8, 2017 Category: Pharmaceuticals Source Type: news

Regeneron and Inovio to conduct Phase Ib/IIa combination trial to treat GBM
Regeneron Pharmaceuticals has entered a clinical study agreement with Inovio Pharmaceuticals to conduct its Phase Ib/IIa clinical trial of REGN2810 in combination with INO-5401 and INO-9012 to treat patients with newly diagnosed glioblastoma multifor … (Source: Drug Development Technology)
Source: Drug Development Technology - May 8, 2017 Category: Pharmaceuticals Source Type: news

Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)
Imfinzi ™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 7, 2017 Category: Pharmaceuticals Source Type: news

GSK and Innoviva report positive results from Phase III trial of Relvar Ellipta to treat asthma
UK-based GlaxoSmithKline (GSK) and US-based Innoviva have reported positive results from the Phase III clinical trial of Relvar Ellipta to treat patients with asthma. (Source: Drug Development Technology)
Source: Drug Development Technology - May 7, 2017 Category: Pharmaceuticals Source Type: news

OncoMed starts dosing in Phase Ia trial of OMP-313M32 for solid tumours
US-based OncoMed Pharmaceuticals has started dosing patients in the Phase Ia clinical trial of anti-TIGIT (OMP-313M32) to treat advanced or metastatic solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - May 7, 2017 Category: Pharmaceuticals Source Type: news

Poxel reports top-line results from Phase IIb trial of imeglimin in Japan
French biopharmaceutical firm Poxel has reported positive top-line results from its Phase IIb clinical trial of imeglimin in Japan to treat patients with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - May 7, 2017 Category: Pharmaceuticals Source Type: news

OncBioMune closes enrolment in Phase I trial of ProscaVax to treat prostate cancer
Biopharmaceutical firm OncBioMune Pharmaceuticals has closed patient enrolment in the Phase I clinical trial of ProscaVax for the treatment of prostate cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - May 4, 2017 Category: Pharmaceuticals Source Type: news

Mereo commences Phase IIb trial of BPS-804 to treat OI
UK-based biopharmaceutical firm Mereo BioPharma has commenced the Phase IIb ASTEROID clinical trial of BPS-804 to treat patients with osteogenesis imperfecta (OI). (Source: Drug Development Technology)
Source: Drug Development Technology - May 4, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: Guiyang Xintian Pharmaceutical, TetraGenetics, Magenta Therapeutics
Chinese pharmaceutical company Guiyang Xintian Pharmaceutical has announced the pricing for its proposed initial public offering (IPO) of shares to raise ¥ 317.02m ($46m) in gross proceeds. (Source: Drug Development Technology)
Source: Drug Development Technology - May 4, 2017 Category: Pharmaceuticals Source Type: news

M & As this week: Kirindo, Owens & Minor
Japanese-based drug store and pharmacies operator Kirindo has announced plans to acquire Medical Trust, a drugstore management firm also based in Japan. (Source: Drug Development Technology)
Source: Drug Development Technology - May 4, 2017 Category: Pharmaceuticals Source Type: news

Genkyotex to initiate Phase II trial of GKT831 to treat PBC
The US Food and Drug Administration (FDA) has accepted French biopharmaceutical firm Genkyotex's investigational new drug (IND) application, allowing the company to initiate a Phase II trial of its GKT831 for the treatment of primary biliary cholangi … (Source: Drug Development Technology)
Source: Drug Development Technology - May 3, 2017 Category: Pharmaceuticals Source Type: news

Soligenix to initiate Phase III trial of SGX942 to treat HNC-associated oral mucositis
Soligenix has obtained clearance from the US Food and Drug Administration (FDA) to initiate a Phase III clinical trial of SGX942 (dusquetide) to treat oral mucositis caused in head and neck cancer (HNC) patients who are receiving chemoradiation (CRT) … (Source: Drug Development Technology)
Source: Drug Development Technology - May 3, 2017 Category: Pharmaceuticals Source Type: news

Stealth begins SBT-20's Phase I/II trial in Netherlands to treat Huntington's disease
Stealth BioTherapeutics has begun the Phase I/II CHALLENGE-HD clinical trial of SBT-20 in the Netherlands to treat patients with early stage Huntington's disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 3, 2017 Category: Pharmaceuticals Source Type: news

April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial
The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of ninteda … (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis
Rydapt ® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytos … (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

Abivax's ABX464 impacts HIV reservoirs in Phase IIa ABX464-004 trial
French biotechnology firm Abivax has reported positive preliminary results from the Phase IIa ABX464-004 clinical trial of ABX464 to treat patients infected with HIV. (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

Concert Pharmaceuticals commences Phase IIa trial to study CTP-543 in alopecia areata
US-based Concert Pharmaceuticals has commenced the Phase IIa clinical trial of CTP-543 to treat patients with moderate-to-severe alopecia areata. (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

Foamix to initiate third Phase III trial of FMX101 in US to treat acne
Israeli-based specialist pharmaceutical firm Foamix Pharmaceuticals is set to initiate a third Phase III clinical trial in the US to investigate FMX101 for the treatment of moderate-to-severe acne. (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

Utilising GPC / SEC to Fine-Tune Physical properties of Synthetic Polymers
To help develop synthetic polymers, researchers mix two or more types of monomers to impart unique physical properties. (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2017 Category: Pharmaceuticals Source Type: news

Cantex begins dosing in Phase II trial of CX-02 to treat recurrent glioblastoma
US-based biopharmaceutical firm Cantex Pharmaceuticals has begun dosing patients in its Phase II clinical trial of CX-02 for the treatment of recurrent glioblastoma. (Source: Drug Development Technology)
Source: Drug Development Technology - May 1, 2017 Category: Pharmaceuticals Source Type: news

Genmab to investigate daratumumab in Phase III combination trial for multiple myeloma
Danish biotechnology firm Genmab is set to investigate the combination of daratumumab with pomalidomide and dexamethasone in its Phase III clinical trial to treat patients with relapsed and refractory multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - May 1, 2017 Category: Pharmaceuticals Source Type: news

Cantex begins dosing Phase II trial of CX-02 to treat recurrent glioblastoma
US-based biopharmaceutical firm Cantex Pharmaceuticals has begun dosing patients in its Phase II clinical trial of CX-02 for the treatment of recurrent glioblastoma. (Source: Drug Development Technology)
Source: Drug Development Technology - May 1, 2017 Category: Pharmaceuticals Source Type: news

Neurotrope reports positive top-line results from Phase II trial of bryostatin-1 for AD
US-based Neurotrope has reported positive top-line results from the Phase II clinical trial of bryostatin-1 for the treatment of moderate-to-severe Alzheimer's disease (AD). (Source: Drug Development Technology)
Source: Drug Development Technology - May 1, 2017 Category: Pharmaceuticals Source Type: news

Jazz Pharmaceuticals reports positive data from TONES 2 trial of JZP-110 in narcolepsy
Irish biopharmaceutical firm Jazz Pharmaceuticals has reported positive efficacy results from the Phase III TONES 2 clinical trial of JZP-110 to treat adults with narcolepsy-associated excessive sleepiness. (Source: Drug Development Technology)
Source: Drug Development Technology - April 27, 2017 Category: Pharmaceuticals Source Type: news

Sage Therapeutics begins dosing in Phase I trial of SAGE-718
US-based biopharmaceutical firm Sage Therapeutics has begun dosing healthy volunteers in its Phase I clinical trial of SAGE-718. (Source: Drug Development Technology)
Source: Drug Development Technology - April 27, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: EpimAb Biotherapeutics, Biohaven Pharmaceutical, Zai Lab (Shanghai)
Chinese-based biopharmaceutical company EpimAb Biotherapeutics has completed a series A venture financing round to raise funds required to advance its proprietary bispecific platform technology and develop a pipeline of candidates in immuno-oncology … (Source: Drug Development Technology)
Source: Drug Development Technology - April 27, 2017 Category: Pharmaceuticals Source Type: news

Ra Pharmaceuticals begins dosing in Phase II trials of RA101495 to treat PNH
US-based Ra Pharmaceuticals has begun dosing patients in the Phase II clinical programme of its RA101495 for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). (Source: Drug Development Technology)
Source: Drug Development Technology - April 26, 2017 Category: Pharmaceuticals Source Type: news

The Medicines Company and Alnylam to initiate Phase III clinical programme of inclisiran
The Medicines Company and Alnylam Pharmaceuticals have entered an agreement with the US Food and Drug Administration (FDA) for the Phase III clinical programme of inclisiran to treat atherosclerotic cardiovascular disease (ASCVD) and familial hyperch … (Source: Drug Development Technology)
Source: Drug Development Technology - April 26, 2017 Category: Pharmaceuticals Source Type: news

Can-Fite to begin Phase III trial of piclidenoson in Israel to treat rheumatoid arthritis
Biotechnology company Can-Fite BioPharma has obtained approval from the Institutional Review Board (IRB) of Barzilai Medical Center in Israel, to begin patient enrolment in the Phase III ACRobat clinical trial of piclidenoson for the treatment of rhe … (Source: Drug Development Technology)
Source: Drug Development Technology - April 26, 2017 Category: Pharmaceuticals Source Type: news

Malvern to Host Webinar on Using Multi-Setection size-exclusion chromatography to Evaluate Biosimilarity
Malvern has announced it will be hosting a new webinar presenting size-exclusion chromatography (SEC) data and discussing the impact of different formulations and external stress conditions on Monoclonal antibodies and biosimilar molecules. (Source: Drug Development Technology)
Source: Drug Development Technology - April 26, 2017 Category: Pharmaceuticals Source Type: news

SillaJen and Transgene commence enrolment in Europe for Phase III trial of Pexa-Vec
South Korean-based biotherapeutics firm SillaJen and French biotechnology firm Transgene have commenced patient enrolment in Europe for the ongoing Phase III PHOCUS clinical trial of Pexa-Vec to treat advanced liver cancer or hepatocellular carcinoma … (Source: Drug Development Technology)
Source: Drug Development Technology - April 25, 2017 Category: Pharmaceuticals Source Type: news

ObsEva commences Phase III trials of OBE2109 to treat uterine fibroids
Swiss-based biopharmaceutical firm ObsEva has commenced its Phase III clinical trial programme of OBE2109 to treat uterine fibroids (UF). (Source: Drug Development Technology)
Source: Drug Development Technology - April 25, 2017 Category: Pharmaceuticals Source Type: news

Capricor reports positive top-line results from Phase I/II trial of CAP-1002 for DMD
US-based biotechnology firm Capricor Therapeutics has reported positive top-line six-month results from the Phase I/II HOPE clinical trial of CAP-1002 to treat duchenne muscular dystrophy (DMD). (Source: Drug Development Technology)
Source: Drug Development Technology - April 25, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb's BMS-986036 meets primary endpoint in Phase II trial to treat NASH
Bristol-Myers Squibb (BMS) has reported positive results from a Phase II clinical trial of BMS-986036 to treat non-alcoholic steatohepatitis (NASH) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2017 Category: Pharmaceuticals Source Type: news

American Regent begins enrolment in Phase III trial of Injectafer to treat heart failure
Japanese pharmaceutical firm Daiichi Sankyo's division, American Regent, has begun patient enrolment in the Phase III HEART-FID clinical trial of Injectafer (ferric carboxymaltose) for the treatment of heart failure with iron deficiency. (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2017 Category: Pharmaceuticals Source Type: news

Tiziana to initiate Phase II trial of milciclib in Israel to treat hepatocellular carcinoma
UK-based biotechnology firm Tiziana Life Sciences has received approval for the initiation of its Phase II clinical trial of milciclib in Israel to treat refractory hepatocellular carcinoma (HCC). (Source: Drug Development Technology)
Source: Drug Development Technology - April 24, 2017 Category: Pharmaceuticals Source Type: news